Expertise in
9
conditions

Ingo B. Runnebaum

Jena, TH, DE 
Expertise in
9
conditions
Jena, TH, DE 

Overview

Ingo Runnebaum practices practicing medicine in Jena, Germany.

Mr. Runnebaum is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy.

He is actively involved in clinical research, co-authoring 160 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Jena, TH, Germany
Other Locations
Munich, BY, Germany
Jean, Germany
Hannover, NI, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 3
View 1 Less Clinical Trial

160 Total Publications

ASO Visual Abstract: Ileocecal and Small-Bowel Involvement are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
ASO Visual Abstract: Ileocecal and Small-Bowel Involvement are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
Journal: Annals of surgical oncology
Published: April 26, 2026

Frequently Asked Questions about Ingo B. Runnebaum

Is Ingo B. Runnebaum a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Ingo B. Runnebaum is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ingo B. Runnebaum participate in research or clinical trials?

Yes. Ingo B. Runnebaum has published 160 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Ingo B. Runnebaum's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Runnebaum's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile